Leo Pharma to withdraw from a quarter of its markets

Citing operating costs, Leo Pharma is dropping out of 22 of its 80 markets.

by christian bundgaard, translated by catherine brett

Published: 06.07.22 at 10:32

Leo Pharma has decided to back out of 22 of its 80 markets, Danish financial daily Børsen reports.

The firm reports that it does not make financial sense for Leo Pharma to continue to operate in these countries, as the price the pharmaceutical company wants for its drugs is not being met.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

ALK to exit Turkish market: "It's bad business if all we get is peanuts"

ALK's Turkish workforce will have look for employment elsewhere | Photo: ALK / PR

A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.

Genmab postpones crucial cancer candidate decision following Abbvie exit

For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.

Genmab says new arbitration builds on a straightforward question

”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.